ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Ligand Pharmaceuticals Incorporated (LGND) Report Updated: Apr 25, 2016 | Print This Page

Ligand Pharmaceuticals Incorporated© quotemedia

Company Profile

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.